SOM Biotech SL   Report issue

For profit Phase 2
Founded: Barcelona Spain (2009)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2014
NCT02191826
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SOM Biotech SL | SOM Innovation Biotech SA

Active Ingredients

Drugs in Phase 2 Trials (3)

bevantolol (1 trial)

ci 775 (1 trial)

tolcapone (tasmar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyloid Neuropathies (Phase 2)

Amyloid Neuropathies, Familial (Phase 2)

Amyloidosis (Phase 2)

Chorea (Phase 2)

Huntington Disease (Phase 2)

Polyneuropathies (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3